By adding one more component to the "cocktail" which slows the malignant cells ability to reproduce (the monoclonal antibody Erbitux). the opportunity to is to have the other two proven killers of malignant cells not have to be used as long or with as high a dose to effect the same result. Ideally this would be more effective, and lessen the morbidity of the treatments themselves.

Brian, stage 4 oral cancer survivor. OCF Founder and Director. The first responsibility of a leader is to define reality. The last is to say thank you. In between, the leader is a servant.